CHARGES HURT J&J: Johnson & Johnson reports second-quarter net income dropped by half due to numerous charges for recalls, litigation and acquisition of orthopedics device maker Synthes.
THE NUMBERS: The health care giant posts net income of $1.41 billion, or 50 cents per share — or $3.63 billion, or $1.30 per share, excluding $2.2 billion in charges. Revenue fell almost a percent to $16.48 billion.
Recommended Stories
THE FORECAST: J&J cut its 2012 profit forecast slightly, to $5 to $5.07 per share, excluding charges. Some recalled consumer products won’t return to stores until 2013, but new drugs are selling well.
